Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of ASP6858 in Healthy Subjects
NCT02359032Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP6858 in chronic kidney disease (CKD) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by adverse events up to 50 days, Safety as assessed by vital signs up to 50 days and 5 more. Started Jan 2015; status: completed.
02
Drugs
ASP6858
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02359032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359032.